Home › Funds › Tetragon Partners GP Ltd › CLDX

Tetragon Partners GP Ltd position in CLDX

CELLDEX THERAPEUTICS INC NEW · Health Care

Tetragon Partners GP Ltd reported holding 290,441 shares of CLDX (CELLDEX THERAPEUTICS INC NEW) in its Q2 2026 13F filing — a position valued at US$10.8M, representing 1.76% of its reported portfolio and ranking #10 among its reported holdings. Tetragon Partners GP Ltd has disclosed CLDX holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

Latest position (Q2 2026)290.44K sh
Reported value held$10.81M
Portfolio Weight1.76%
First reportedQ4 2024
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Tetragon Partners GP Ltd's CLDX position evolved

Tetragon Partners GP Ltd first disclosed a stake in CLDX in Q4 2024 at 192,000 shares (US$4.9M). The position peaked in Q2 2026 at 290,441 shares, worth US$10.8M. Across 7 filings, Tetragon Partners GP Ltd increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 290,441 shares valued at US$10.8M — a reduction of -21,875 shares quarter over quarter.. Notable position changes include a 36% increase in Q1 2025 (shares rose 12% over the following quarter), a 28% increase in Q1 2026 (shares rose 17% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 192.00K $4.85M New
Q1 2025 261.00K $4.74M Add
Q2 2025 316.15K $6.43M Add
Q3 2025 303.60K $7.85M Reduce
Q4 2025 243.80K $6.62M Reduce
Q1 2026 312.32K $9.91M Add
Q2 2026 290.44K $10.81M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CLDX and 13F data

CLDX (CELLDEX THERAPEUTICS INC NEW) is a Health Care company. 44 other funds we track also report a position in CLDX — the largest reported positions include Kynam Capital Management, LP (US$198.1M), Deep Track Capital, LP (US$109.4M), Logos Global Management LP (US$78.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CLDX

All CLDX fund holders →

FAQ

How long has Tetragon Partners GP Ltd held CLDX?

Tetragon Partners GP Ltd has disclosed CLDX holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

What is Tetragon Partners GP Ltd's current position in CLDX?

As of Q2 2026, Tetragon Partners GP Ltd holds 290.44K shares of CLDX (CELLDEX THERAPEUTICS INC NEW), valued at $10.81M, representing 1.76% of its reported portfolio and ranking #10.

Has Tetragon Partners GP Ltd been buying or selling CLDX?

In the latest 13F filing (Q2 2026), Tetragon Partners GP Ltd reduced its position in CLDX. The position peaked in Q2 2026 at 290.44K shares.

Which other funds hold CLDX?

Other major institutional holders of CLDX include Kynam Capital Management, LP, Deep Track Capital, LP, Logos Global Management LP, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.